{"preliminary_commentary":{"by_channel":{"x_thread":30,"podcast":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04294810\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"SKYSCRAPER-01","nct_id":"NCT04294810","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=skyscraper-01-nct04294810. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SKYSCRAPER-01","arms":[{"description":"Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.","label":"Tiragolumab + Atezolizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.","label":"Placebo + Atezolizumab","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-12-30","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":620,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"Tiragolumab","otherNames":["MTIG7192A"],"type":"DRUG"},{"name":"Matching Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-01-30","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-12-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months)"},{"measure":"Overall Survival (OS) in the Primary Analysis Set","timeFrame":"From randomization to death from any cause (up to approximately 59 months)"},{"measure":"Percentage of Participants With Adverse Events (AEs)","timeFrame":"Up to approximately 59 months"},{"measure":"Percentage of Participants With Cytokine-Release Syndrome (CRS)","timeFrame":"Up to approximately 59 months"}],"references":[{"citation":"Peters S, Herbst R, Horinouchi H, Paz-Ares L, Johnson M, Solomon BJ, Gumus M, Erman M, Bondarenko I, Kim DW, Felip E, Morabito A, Bryl M, Urban L, Nosaki K, Reck M, Meng R, Stroud C, Kundu P, Wen X, Patil NS, Huang M, Troutman S, Matheny C, Cho BC. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2026 Sep;44(25):2400-2408. doi: 10.1200/JCO-25-02777. Epub 2026 Jul 27.","pmid":"42507968","type":"DERIVED"},{"citation":"Beaufils A, De Martino J, Jiang X, Blanchard T, Fraunhoffer N, Mendes D, Pignolet C, Bourega T, Meneghetti AR, Sainath S, Albuquerque M, Colnot N, Tihy M, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lecomte T, Biagi J, Artru P, Evesque L, Lambert A, Renouf DJ, Mauduit M, Dusetti NJ, Hammel P, Conroy T, Bachet JB, de Mestier L, Rebours V, Cros J, Kather JN, Nicolle R. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. J Clin Oncol. 2026 Sep 10;44(26):2507-2516. doi: 10.1200/JCO-26-00327. Epub 2026 Jul 27.","pmid":"42507965","type":"DERIVED"}],"start_date":{"date":"2020-03-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04294810"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/skyscraper-01-nct04294810"}